United Way Muscatine County steps in to provide for local families
When a reorganization of Early Childhood Iowa left Muscatine County without local leadership for coordinating key early childhood and family programs in fall 2024, United Way Muscatine County stepped in to ensure vital services for families remained intact, according to a news release.
As Muscatine County became part of a five-county Early Childhood Iowa (ECI) region, the absence of a local director jeopardized access to preschool tuition and transportation scholarships. United Way Muscatine County assumed responsibility for managing these funds and preserving equitable access to preschool for local families, the release says.
United Way also took on oversight of the Muscatine County Community Partnerships for Protecting Children (CPPC) funds, which provide funding to strengthen local child abuse prevention efforts. This role positioned the organization to apply for the newly restructured Iowa Child Abuse Prevention Program (ICAPP) grants on behalf of the region—a shift that now favors more collaborative, regionally organized applications.
'Our community has long-standing relationships and a shared vision for child and family success,' said Kim Warren, executive director of AIM at United Way Muscatine County. 'That level of collaboration allowed us to move quickly and effectively when the structure changed. It's a testament to how united our local partners are around supporting children and families.'
Thanks to strong community partnerships and an existing network of service providers, United Way Muscatine County successfully secured ICAPP and ECI funding for a range of programs including:
● Family Program Services delivered through the Muscatine Community YMCA, supporting Grandparents Raising Grandchildren, Teen Parents, and Mujeres Latinas—along with offering free childcare during program participation.
● Sexual Abuse Prevention Training provided to the community by Muscatine Community YMCA facilitators.
● Coordinated Intake through Public Health, which assesses newborn families for risk factors and connects them quickly to the services they need, including home visitation, parenting programs, and more.
● Preschool Tuition and Transportation Scholarships for families whose income falls below 200% of the federal poverty level, reducing barriers to early education.
'Receiving this funding is absolutely vital to the operation of our essential family support programming,' says Bret Olson, Executive Director of the YMCA. 'Without these crucial funds, it simply wouldn't be possible to provide this invaluable support to our community. We're especially grateful for Kim Warren from AIM, whose leadership was instrumental in ensuring these funds remain right here in our community.'
Muscatine County continues to outperform in key early childhood metrics, including home visitation participation, in part due to the strong integration of coordinated intake efforts. These services, combined with wraparound supports like the preschool scholarships, Imagination Library, CPPC mini-grants, and Y Family Program Services, create a robust safety net for families with young children. Thanks to the work of Aligned Impact Muscatine County, an education initiative of United Way Muscatine County, $192,759 will continue to fund services for children and families in Muscatine County through fiscal year 2026.
'While some regions in our state were unable to form the collaborations needed to mobilize applications, Muscatine County's existing collaboration, shared goals, and trust allowed us to respond immediately,' Warren added. 'We are proud to be a trusted leader in maintaining and expanding these essential programs.'
United Way Muscatine County is committed to continuing its leadership in managing state-funded early childhood and family support services—ensuring every child and family in the county has the opportunity to thrive.
For more information, contact Kim Warren at kim@unitedwaymuscatine.org or 563-594-6835.
About United Way Muscatine County
United Way Muscatine County is a nonprofit organization with a mission to mobilize resources to empower the greater Muscatine community to improve the lives of people in need. Through partnerships with local organizations, United Way Muscatine County focuses on increasing household independence through education and housing. The organization mobilizes volunteers, donors, and advocates to make a lasting difference across the whole county.
About Aligned Impact
Muscatine County: Aligned Impact Muscatine County (AIM) is a cradle-to-career collective impact initiative of United Way Muscatine County that partners with over 35 organizations to align community resources and identify effective practices for implementation to reduce achievement gaps and improve outcomes for all students and families.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
05-06-2025
- Yahoo
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma
SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the New Drug Application (NDA) for the combination of sintilimab and fruquintinib for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor (TKI) has been accepted for review by the China National Medical Products Administration (NMPA). The NDA is supported by data from FRUSICA-2, a randomized, open-label, active-controlled registration study evaluating the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of advanced renal cell carcinoma. The study has met its primary endpoint of progression free survival (PFS), as assessed by blinded independent central review (BICR) according to RECIST 1.1 criteria. The combination also demonstrated improvements in secondary endpoints including objective response rate (ORR) and duration of response (DoR). The safety profile was tolerable and no new safety signals were observed. Data from FRUSICA-2 will be submitted for presentation at an upcoming scientific conference. Additional details may be found at using identifier NCT05522231. Dr Hui Zhou, Senior Vice President of Innovent, stated: "The second NDA acceptance of sintilimab and fruquintinib combination represents a significant step toward providing a more effective treatment option for patients with second line advanced renal cell carcinoma in China. Our PD-1 inhibitor, sintilimab (TYVYT®), has solidified its position as a cornerstone of immuno-oncology (IO) therapy with this NDA as its 10th indication, marking a meaningful milestone in lifecycle management and clinical value optimization." Dr Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED, stated: "Kidney cancer continues to pose significant challenges in China, with limited treatment options for patients who fail first-line therapies. Submitting this NDA for the fruquintinib and sintilimab combination for advanced renal cell carcinoma marks an important step in our efforts to address this unmet need. We are dedicated to making this combination therapy available to patients with renal cell carcinoma. At the same time, through ongoing research, we remain focused on exploring the full potential of this combination, as well as advancing our broader pipeline across multiple cancer types, to provide more patients with new and effective treatment options." In December 2024, the combination of sintilimab and fruquintinib received conditional approval from the China NMPA for the treatment of patients with advanced mismatch repair proficient (pMMR) endometrial cancer who have failed prior systemic therapy and are not candidates for curative surgery or radiation, based on data from the FRUSICA-1 study (NCT03903705). About Kidney Cancer and Renal Cell Carcinoma It is estimated that approximately 435,000 new patients were diagnosed with kidney cancer worldwide in 2022.[i] In China, an estimated 74,000 new patients were diagnosed with kidney cancer in 2022.[ii] Approximately 90% of kidney tumors are RCC. About Sintilimab Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is a PD-1 immunoglobulin G4 monoclonal antibody co-developed and co-commercialized by Innovent and Eli Lilly and Company, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.[iii] In China, sintilimab has been approved and included in the updated NRDL for seven indications. The updated NRDL reimbursement scope for TYVYT® (sintilimab injection) includes: For the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy; For the first-line treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer lacking EGFR or ALK driver gene mutations; For the treatment of patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer who progressed after EGFR-TKI therapy; For the first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer; For the first-line treatment of unresectable or metastatic hepatocellular carcinoma with no prior systematic treatment; For the first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma; For the first-line treatment of unresectable locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma. Furthermore, sintilimab's eighth indication, in combination with fruquintinib for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation, was conditional approved by the NMPA in December 2024. Two NDAs for sintilimab are currently under the NMPA review, including: In combination with ipilimumab as neoadjuvant treatment for resectable MSI-H/dMMR colon cancer is under the NMPA review and has been granted Priority Review designation; In combination with fruquintinib for the treatment of patients with locally advanced or metastatic renal cell carcinoma who failed prior treatment with one TKI. In addition, two clinical studies of sintilimab have met their primary endpoints: Phase 2 clinical study of sintilimab monotherapy as second-line treatment of esophageal squamous cell carcinoma; Phase 3 clinical study of sintilimab monotherapy as second-line treatment for squamous non-small cell lung cancer with disease progression following platinum-based chemotherapy. About Fruquintinib Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3. VEGFR inhibitors play a pivotal role in inhibiting tumor angiogenesis. Fruquintinib was designed to have enhanced selectivity that limits off-target kinase activity, allowing for drug exposure that achieves sustained target inhibition and flexibility for potential use as part of a combination therapy.[iv] About Fruquintinib Approvals Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. It is approved for the treatment of patients with metastatic colorectal cancer who have previously received fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy, and those who have previously received or are not suitable to receive anti-VEGF therapy or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild-type) in China. It was included in the China National Reimbursement Drug List (NRDL) in January 2020. Since its launch in China, over 100,000 patients with colorectal cancer have been treated with fruquintinib. The combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab injection) has conditional approval in China for the treatment of patients with advanced pMMR endometrial cancer who have failed prior systemic therapy and are not candidates for curative surgery or radiation. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®. Fruquintinib received approval for the treatment of previously treated metastatic colorectal cancer in the US, Europe, Japan and many other countries around the world. The safety and efficacy of fruquintinib for the following investigational uses have not been established and there is no guarantee that it will receive health authority approval or become commercially available in any country for the uses being investigated: About Fruquintinib for Second-line Treatment of RCC Single-agent targeted therapy continues to be one of the primary choices for first-line treatment of advanced RCC in China. Notably, advanced RCC patients who have experienced failure with single-agent targeted therapy previously still indicate an unmet medical need. Results from a proof-of-concept Phase Ib/II study of fruquintinib plus sintilimab were published in Targeted Oncology in January 2025. The combination demonstrated promising efficacy and a tolerable safety profile in this setting. At the data cutoff of October 9, 2024, all 20 enrolled previously treated patients were evaluable for efficacy, with a median follow-up duration of 45.7 months. The confirmed ORR was 60.0% and DCR was 85.0%. Median DoR was 13.9 months and median PFS was 15.9 months. Overall survival (OS) was not reached, and the 36-month OS rate was 58.3%.[v] About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: （1）Innovent does not recommend the use of any unapproved drug (s)/indication (s). （2）Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company. About HUTCHMED HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit or follow us on LinkedIn. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Reference: [i] The Global Cancer Observatory, kidney cancer fact sheet. Accessed February 19, 2025. [ii] The Global Cancer Observatory, China fact sheet. Accessed February 19, 2025. [iii] Wang J, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs 2019;11(8): 1443-1451. DOI: 10.1080/19420862.2019.1654303. [iv] Sun Q, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. doi: 10.4161/15384047.2014.964087. [v] Xu H, et al. Fruquintinib Plus Sintilimab in Patients with Treatment‑Naïve and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial. Targeted Oncology. 2025; 20:113–125. View original content: SOURCE Innovent Biologics Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Geek Tyrant
03-06-2025
- Geek Tyrant
New Trailer For The Imagination-Fueled Fantasy Film SKETCH - "Unleash Your Inner Monsters" — GeekTyrant
Angel Studios has released a great new trailer for its imagination-fueled dark fantsy family film Sketch . The movie has been getting a lot of great and positive reviews, and it's on that I've very mush looking forward to watching. I enjoy watch these kinds of adventure films that lean into the imagination of kids and monsters. As I'm watching the trailer, I'm reminded of the films that I loved as a kid, and this movie looks like it captures the spirit and energy of those movies. In the film, 'When 10-year-old Amber's (Bianca Belle) comically dark drawings start coming to life, her small town descends into chaos. Now, her family must face Amber's living nightmares head-on before her creations end up destroying everything.' The movie is described as 'Dazzlingly inventive.. take[s] the wide-eyed wonder of a Steven Spielberg, the impish mischief of a Joe Dante, plus the vibrant visuals of prime Pixar and somehow blitz[s] them together in a Magic Bullet blender' The movie comes from filmmaker Seth Worley making his feature directorial debut, and it stars Tony Hale, D'Arcy Carden, Kue Lawrence, Kalon Cox, Jaxen Kenner, Genesis Rose Brown, and introducing Bianca Belle as Amber. Angel Studios will release Sketch in theaters starting on August 6th, 2025.
Yahoo
30-05-2025
- Yahoo
United Way Muscatine County steps in to provide for local families
When a reorganization of Early Childhood Iowa left Muscatine County without local leadership for coordinating key early childhood and family programs in fall 2024, United Way Muscatine County stepped in to ensure vital services for families remained intact, according to a news release. As Muscatine County became part of a five-county Early Childhood Iowa (ECI) region, the absence of a local director jeopardized access to preschool tuition and transportation scholarships. United Way Muscatine County assumed responsibility for managing these funds and preserving equitable access to preschool for local families, the release says. United Way also took on oversight of the Muscatine County Community Partnerships for Protecting Children (CPPC) funds, which provide funding to strengthen local child abuse prevention efforts. This role positioned the organization to apply for the newly restructured Iowa Child Abuse Prevention Program (ICAPP) grants on behalf of the region—a shift that now favors more collaborative, regionally organized applications. 'Our community has long-standing relationships and a shared vision for child and family success,' said Kim Warren, executive director of AIM at United Way Muscatine County. 'That level of collaboration allowed us to move quickly and effectively when the structure changed. It's a testament to how united our local partners are around supporting children and families.' Thanks to strong community partnerships and an existing network of service providers, United Way Muscatine County successfully secured ICAPP and ECI funding for a range of programs including: ● Family Program Services delivered through the Muscatine Community YMCA, supporting Grandparents Raising Grandchildren, Teen Parents, and Mujeres Latinas—along with offering free childcare during program participation. ● Sexual Abuse Prevention Training provided to the community by Muscatine Community YMCA facilitators. ● Coordinated Intake through Public Health, which assesses newborn families for risk factors and connects them quickly to the services they need, including home visitation, parenting programs, and more. ● Preschool Tuition and Transportation Scholarships for families whose income falls below 200% of the federal poverty level, reducing barriers to early education. 'Receiving this funding is absolutely vital to the operation of our essential family support programming,' says Bret Olson, Executive Director of the YMCA. 'Without these crucial funds, it simply wouldn't be possible to provide this invaluable support to our community. We're especially grateful for Kim Warren from AIM, whose leadership was instrumental in ensuring these funds remain right here in our community.' Muscatine County continues to outperform in key early childhood metrics, including home visitation participation, in part due to the strong integration of coordinated intake efforts. These services, combined with wraparound supports like the preschool scholarships, Imagination Library, CPPC mini-grants, and Y Family Program Services, create a robust safety net for families with young children. Thanks to the work of Aligned Impact Muscatine County, an education initiative of United Way Muscatine County, $192,759 will continue to fund services for children and families in Muscatine County through fiscal year 2026. 'While some regions in our state were unable to form the collaborations needed to mobilize applications, Muscatine County's existing collaboration, shared goals, and trust allowed us to respond immediately,' Warren added. 'We are proud to be a trusted leader in maintaining and expanding these essential programs.' United Way Muscatine County is committed to continuing its leadership in managing state-funded early childhood and family support services—ensuring every child and family in the county has the opportunity to thrive. For more information, contact Kim Warren at kim@ or 563-594-6835. About United Way Muscatine County United Way Muscatine County is a nonprofit organization with a mission to mobilize resources to empower the greater Muscatine community to improve the lives of people in need. Through partnerships with local organizations, United Way Muscatine County focuses on increasing household independence through education and housing. The organization mobilizes volunteers, donors, and advocates to make a lasting difference across the whole county. About Aligned Impact Muscatine County: Aligned Impact Muscatine County (AIM) is a cradle-to-career collective impact initiative of United Way Muscatine County that partners with over 35 organizations to align community resources and identify effective practices for implementation to reduce achievement gaps and improve outcomes for all students and families. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
